These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 18297550

  • 1. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
    Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF.
    Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
    [Abstract] [Full Text] [Related]

  • 2. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [Abstract] [Full Text] [Related]

  • 3. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A, Cerletti C, de Gaetano G.
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [Abstract] [Full Text] [Related]

  • 4. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
    Kobsar AL, Koessler J, Rajkovic MS, Brunner KP, Steigerwald U, Walter U.
    Platelets; 2010 Dec; 21(2):112-6. PubMed ID: 20085435
    [Abstract] [Full Text] [Related]

  • 5. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D, Glenn JR, White AE, Fox SC, van Giezen H, Nylander S, Heptinstall S.
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [Abstract] [Full Text] [Related]

  • 6. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
    Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD.
    Thromb Haemost; 2007 Jul; 98(1):192-200. PubMed ID: 17598013
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
    Koessler J, Kobsar AL, Rajkovic MS, Schafer A, Flierl U, Pfoertsch S, Bauersachs J, Steigerwald U, Rechner AR, Walter U.
    Platelets; 2011 Jul; 22(1):20-7. PubMed ID: 20873965
    [Abstract] [Full Text] [Related]

  • 10. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.
    Manolopoulos P, Glenn JR, Fox SC, May JA, Dovlatova NL, Tang SW, Thomas NR, Ralevic V, Heptinstall S.
    Platelets; 2008 Mar; 19(2):134-45. PubMed ID: 18297551
    [Abstract] [Full Text] [Related]

  • 11. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y, Sugidachi A, Ogawa T, Jakubowski JA, Hashimoto M, Isobe T, Otsuguro K, Asai F.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):276-82. PubMed ID: 17996866
    [Abstract] [Full Text] [Related]

  • 12. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
    Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, Jakubowski JA, Olofsson S, Wallentin L, Siegbahn A.
    Am Heart J; 2009 Mar 28; 157(3):562.e1-9. PubMed ID: 19249429
    [Abstract] [Full Text] [Related]

  • 13. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA, Asai F.
    Thromb Haemost; 2005 Sep 28; 94(3):593-8. PubMed ID: 16268477
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
    Dovlatova N, Wijeyeratne YD, Fox SC, Manolopoulos P, Johnson AJ, White AE, Latif ML, Ralevic V, Heptinstall S.
    Thromb Haemost; 2008 Aug 28; 100(2):261-70. PubMed ID: 18690346
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A, Virtanen KS, Reséndiz JC, Mikkelsson J, Viiri LE, Karhunen PJ, Lassila R.
    Thromb Res; 2009 Jun 28; 124(2):193-8. PubMed ID: 19232433
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
    Behan MW, Fox SC, Heptinstall S, Storey RF.
    Platelets; 2005 Mar 28; 16(2):73-80. PubMed ID: 15823862
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
    Dobesh PP.
    Pharmacotherapy; 2009 Sep 28; 29(9):1089-102. PubMed ID: 19698014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.